Comprehensive Genomic Profiling (CGP)
CGP is an approach that utilizes next-generation sequencing (NGS) to assess multiple established biomarkers present within a solid tumor. CGP detects at a genomic resolution that allows identification of variant classes such as SNVs, indels, CNVs, select fusions, as well as cancer genomic signatures such as tumor mutational burden (TMB) and microsatellite instability (MSI).
The breadth of this single assay allows for a robust understanding of a tumor profile alleviating the need to use multiple tumor specific panels or different modalities of testing.
"At LifeStrands Genomics Australia, we rely heavily on Twist’s NGS probes and reagents across nearly all our assays... Twist’s probe design flexibility and scalability have allowed us to tailor both DNA and RNA panels that suit a wide range of solid tumours without compromising sensitivity or turnaround times. We view Twist not just as a vendor, but as a strategic partner in advancing precision oncology. ”
* The results are specific to the institution to which they were obtained. The results presented are customer-specific and should not be interpreted as indicative of performance across all institutions.
Dr. Vivek Rathi, MD MSc FRCPA
Medical Director
LifeStrands Genomics Australia
(Genoox User)
Complete Solution Set for Solid
Tumor DNA Analysis
Library Preparation
High performing library preparation and target enrichment
PRODUCT OFFERINGS
Sequencing
Compatible solutions to sequence on your preferred platform
Twist Oncology DNA CGP panel can be paired with our modular reagent solutions to enable platform compatibility.
Analysis Options
Analysis solutions to meet you lab’s needs
Twist offers a variety of bioinformatic solutions for CGP analysis.
Comprehensive Genomic Profiling (CGP)
CGP is an approach that utilizes next-generation sequencing (NGS) to assess multiple established biomarkers present within a solid tumor. CGP detects at a genomic resolution that allows identification of variant classes such as SNVs, indels, CNVs, select fusions, as well as cancer genomic signatures such as tumor mutational burden (TMB) and microsatellite instability (MSI).
The breadth of this single assay allows for a robust understanding of a tumor profile alleviating the need to use multiple tumor specific panels or different modalities of testing.
"At LifeStrands Genomics Australia, we rely heavily on Twist’s NGS probes and reagents across nearly all our assays... Twist’s probe design flexibility and scalability have allowed us to tailor both DNA and RNA panels that suit a wide range of solid tumours without compromising sensitivity or turnaround times. We view Twist not just as a vendor, but as a strategic partner in advancing precision oncology. ”
* The results are specific to the institution to which they were obtained. The results presented are customer-specific and should not be interpreted as indicative of performance across all institutions.
Dr. Vivek Rathi, MD MSc FRCPA
Medical Director
LifeStrands Genomics Australia
(Genoox User)
Complete Solution Set for Solid
Tumor DNA Analysis
Library Preparation
High performing library preparation and target enrichment
PRODUCT OFFERINGS
Sequencing
Compatible solutions to sequence on your preferred platform
Twist Oncology DNA CGP panel can be paired with our modular reagent solutions to enable platform compatibility.
Analysis Options
Analysis solutions to meet you lab’s needs
Twist offers a variety of bioinformatic solutions for CGP analysis.
Broad Coverage of Tumor Types
Twist’s DNA CGP panel covers a broad set of solid tumor types and associated mutations enabling a single panel to be utilized across many tissue types. For a complete listing of all genes, SNPs, and hotspots covered by the panel, please refer to the technical documents in the resources tab or click download button in the sidebar.
The DNA CGP panel is designed to cover mutations such as single nucleotide variants (SNVs), Insertions and deletions (InDels), and copy number alterations and gene rearrangements. Additional genomic signatures scoring such as tumor mutational burden (TMB) and microsatellite instability (MSI) is available when combined with Twist’s bioinformatic analysis solution, or a 3rd party analysis software.
Click the button below to download the contents of this panel including the genes covered.
Broad Coverage of Tumor Types
Twist’s DNA CGP panel covers a broad set of solid tumor types and associated mutations enabling a single panel to be utilized across many tissue types. For a complete listing of all genes, SNPs, and hotspots covered by the panel, please refer to the technical documents in the resources tab or click download button in the sidebar.
The DNA CGP panel is designed to cover mutations such as single nucleotide variants (SNVs), Insertions and deletions (InDels), and copy number alterations and gene rearrangements. Additional genomic signatures scoring such as tumor mutational burden (TMB) and microsatellite instability (MSI) is available when combined with Twist’s bioinformatic analysis solution, or a 3rd party analysis software.
Click the button below to download the contents of this panel including the genes covered.
Twist Oncology - DNA CGP Panel - 2.4 Mb
116352
Twist Oncology DNA CGP Panel, 2.4 Mb, 2 Reactions116353
Twist Oncology DNA CGP Panel, 2.4 Mb, 12 Reactions116359
Twist Oncology DNA CGP Panel, 2.4 Mb, 96 ReactionsTwist Oncology - DNA CGP Panel - 2.4 Mb
116352
Twist Oncology DNA CGP Panel, 2.4 Mb, 2 Reactions116353
Twist Oncology DNA CGP Panel, 2.4 Mb, 12 Reactions116359
Twist Oncology DNA CGP Panel, 2.4 Mb, 96 Reactions
Product Sheet
Data Files
Application Note
Download our Cancer Research eBook
Learn how leading researchers are leveraging tools built on synthetic DNA to advance their research in cancer model development, drug discovery, diagnostics, and more.
EXPLORE MORE OF OUR PRODUCTS
Related products
Twist products are for research use only. The products presented here are not intended for the diagnosis, prevention, or treatment of a disease or condition. Twist Bioscience assumes no liability regarding use of the product for applications in which it is not intended. The results are specific to the institution to which they were obtained. The results presented are customer-specific and should not be interpreted as indicative of performance across all institutions.
